Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: New implication for Kawasaki disease (KD) treatment

Biochemical and Biophysical Research Communications

Volumn 437, Issue 2, 2013, Pages 250-255

  Shen, Jie ^a   Liang, Li ^a   Wang, Chunlin ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

AMPK; ERK; Kawasaki disease; LPS; Perifosine; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMPK; ERK; KAWASAKI DISEASE; LPS; PERIFOSINE; TNFΑ;

ANIMALS; CELL LINE; ENZYME ACTIVATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PHOSPHORYLCHOLINE; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880731020     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.055     Document Type: Article

References (29)

1. Dajani A.S., Taubert K.A., Gerber M.A., Shulman S.T., Ferrieri P., Freed M., Takahashi M., Bierman F.Z., Karchmer A.W., Wilson W., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776-1780.
2. Kato H., Koike S., Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979, 63:175-179.
3. Takahashi K., Oharaseki T., Yokouchi Y. Pathogenesis of Kawasaki disease. Clin. Exp. Immunol. 2011, 164(Suppl. 1):20-22.
4. Taubert K.A., Rowley A.H., Shulman S.T. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr. Infect. Dis. J. 1994, 13:704-708.
5. Lin C.Y., Lin C.C., Hwang B., Chiang B.N. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur. J. Pediatr. 1993, 152:309-312.
6. Eberhard B.A., Andersson U., Laxer R.M., Rose V., Silverman E.D. Evaluation of the cytokine response in Kawasaki disease. Pediatr. Infect. Dis. J. 1995, 14:199-203.
7. Leung D.Y., Geha R.S., Newburger J.W., Burns J.C., Fiers W., Lapierre L.A., Pober J.S. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 1986, 164:1958-1972.
8. Lang B.A., Silverman E.D., Laxer R.M., Lau A.S. Spontaneous tumor necrosis factor production in Kawasaki disease. J. Pediatr. 1989, 115:939-943.
9. Weiss J.E., Eberhard B.A., Chowdhury D., Gottlieb B.S. Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 2004, 31:808-810.
10. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2003, 2:1093-1103.
11. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 1999, 59:2457-2463.
12. Cirstea D., Hideshima T., Rodig S., Santo L., Pozzi S., Vallet S., Ikeda H., Perrone G., Gorgun G., Patel K., Desai N., Sportelli P., Kapoor S., Vali S., Mukherjee S., Munshi N.C., Anderson K.C., Raje N. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol. Cancer Ther. 2010, 9:963-975.
13. Crul M., Rosing H., de Klerk G.J., Dubbelman R., Traiser M., Reichert S., Knebel N.G., Schellens J.H., Beijnen J.H., ten Bokkel Huinink W.W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer 2002, 38:1615-1621.
14. Van Ummersen L., Binger K., Volkman J., Marnocha R., Tutsch K., Kolesar J., Arzoomanian R., Alberti D., Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 2004, 10:7450-7456.
15. Fei H.R., Chen G., Wang J.M., Wang F.Z. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology 2010, 62:449-460.
16. Papa V., Tazzari P.L., Chiarini F., Cappellini A., Ricci F., Billi A.M., Evangelisti C., Ottaviani E., Martinelli G., Testoni N., McCubrey J.A., Martelli A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008, 22:147-160.
17. Ji C., Yang Y.L., Yang Z., Tu Y., Cheng L., Chen B., Xia J.P., Sun W.L., Su Z.L., He L., Bi Z.G. Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention?. Cell. Signal. 2012, 24:1781-1789.
18. Sun H., Yu T., Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett. 2011, 310:118-128.
19. Momota H., Nerio E., Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 2005, 65:7429-7435.
20. Li X., Luwor R., Lu Y., Liang K., Fan Z. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006, 25:525-535.
21. Giri S., Nath N., Smith B., Viollet B., Singh A.K., Singh I. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J. Neurosci. 2004, 24:479-487.
22. Dumitru C.D., Ceci J.D., Tsatsanis C., Kontoyiannis D., Stamatakis K., Lin J.H., Patriotis C., Jenkins N.A., Copeland N.G., Kollias G., Tsichlis P.N. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000, 103:1071-1083.
23. Herlaar E., Brown Z. P38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today 1999, 5:439-447.
24. Schwabe R.F., Brenner D.A. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G583-589.
25. Hattori Y., Suzuki K., Hattori S., Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47:1183-1188.
26. Scherle P.A., Jones E.A., Favata M.F., Daulerio A.J., Covington M.B., Nurnberg S.A., Magolda R.L., Trzaskos J.M. Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J. Immunol. 1998, 161:5681-5686.
27. Guha M., O'Connell M.A., Pawlinski R., Hollis A., McGovern P., Yan S.F., Stern D., Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001, 98:1429-1439.
28. Park Y.C., Lee C.H., Kang H.S., Chung H.T., Kim H.D. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages. Biochem. Biophys. Res. Commun. 1997, 240:692-696.
29. Inoki K., Kim J., Guan K.L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 2012, 52:381-400.